ArticlePLoS neglected tropical diseases2025
Bacillus cereus biovar anthracis causes inhalational anthrax-like disease in rabbits that is treatable with medical countermeasures.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DecodingPlants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Bacillus anthracis is a zoonotic organism that causes the disease anthrax due to the activity of virulence factors harbored on plasmids pXO1 and pXO2. Inhalation of B. anthracis spores results in pneumonic disease that progresses quickly, and often results in lethality in the absence of medical countermeasure (MCM) intervention. Recently, reports have identified Bacillus cereus isolates that possess pXO1 and pXO2-like plasmids and cause an anthrax-like disease. These isolates have been named B. cereus biovar anthracis, or Bcbva. To evaluate disease course of Bcbva, the inhalational median lethal dose (INHLD50) was determined for two isolates, Bcbva Cameroon (CA) and Bcbva Cote d'Ivoire (CI), using the New Zealand white (NZW) rabbit inhalation anthrax model and compared to established B. anthracis inhalation data. Furthermore, disease progression and anthrax MCM efficacies were evaluated by quantifying temperature responses, bacteremia, and virulence factor production in both survivor and non-survivor animals. This study determined that the rabbit INHLD50 values for Bcbva CA and CI were similar to that published for B. anthracis Ames. The mean time to significant increase in body temperature (SIBT) and death were dose dependent for both Bcbva isolates, and all animals that succumbed to aerosol exposure displayed SIBT prior to death. Serum hyaluronic acid concentration increased prior to mortality in animals challenged with Bcbva and differences were observed in serum protective antigen concentration in animals challenged with Bcbva compared to B. anthracis. Pre-exposure vaccination with Anthrax Vaccine Adsorbed (AVA) and post-exposure prophylaxis of levofloxacin with or without AVA vaccination were effective against a challenge of ~200 INHLD50 of Bcbva CA or CI. Collectively, these data suggest that anthrax-like disease caused by Bcbva is similar to that caused by B. anthracis Ames 2084, and that currently available countermeasures are effective against inhalation exposure to Bcbva.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.